Ser1452

Site Information
RPPAEKLsPNPPNLt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3191581

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 12 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ) , multiple reaction monitoring (MRM) ( 12 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 , 12 )
Disease tissue studied:	bladder cancer ( 2 ) , breast cancer ( 8 , 14 , 23 ) , breast ductal carcinoma ( 14 ) , HER2 positive breast cancer ( 5 ) , luminal A breast cancer ( 5 ) , luminal B breast cancer ( 5 ) , breast cancer, surrounding tissue ( 5 ) , breast cancer, triple negative ( 5 , 14 ) , cervical cancer ( 36 ) , cervical adenocarcinoma ( 36 ) , colorectal cancer ( 2 ) , colorectal carcinoma ( 2 ) , kidney cancer ( 2 ) , leukemia ( 2 , 27 , 44 ) , acute myelogenous leukemia ( 27 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 22 ) , acute megakaryoblastic leukemia (M7) ( 22 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 22 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 22 ) , chronic myelogenous leukemia ( 44 ) , lung cancer ( 2 , 11 , 18 , 24 ) , non-small cell lung cancer ( 2 , 24 ) , non-small cell lung adenocarcinoma ( 2 , 11 , 18 ) , lymphoma ( 2 , 15 ) , Burkitt's lymphoma ( 15 ) , follicular lymphoma ( 15 ) , mantle cell lymphoma ( 15 ) , neuroblastoma ( 1 , 2 ) , ovarian cancer ( 2 , 12 , 14 ) , ovarian epithelial carcinoma ( 2 , 12 ) , prostate cancer ( 2 ) , melanoma skin cancer ( 10 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 34 ) , 293 (epithelial) ( 38 ) , 293E (epithelial) ( 29 ) , 5637 (bladder cell) ( 2 ) , 786-O (renal) [VHL (human), transfection] ( 9 ) , 786-O (renal) ( 2 , 9 ) , A2780 (ovarian) ( 2 ) , A549 (pulmonary) ( 2 ) , AML-193 (monocyte) ( 22 ) , BJAB (B lymphocyte) ( 15 ) , breast ( 5 , 14 ) , BT-474 (breast cell) ( 8 ) , Caco-2 (intestinal) ( 2 ) , Calu 6 (pulmonary) ( 24 ) , CLB-Bar ( 1 ) , CMK (megakaryoblast) ( 22 ) , DG75 (B lymphocyte) ( 33 ) , DU 145 (prostate cell) ( 2 ) , ES2 (ovarian) ( 2 , 12 ) , FL-18 (B lymphocyte) ( 15 ) , FL-318 (B lymphocyte) ( 15 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 25 ) , Flp-In T-Rex-293 (epithelial) ( 25 ) , H2009 (pulmonary) ( 24 ) , H2887 (pulmonary) ( 24 ) , HEK293T (epithelial) ( 2 , 12 ) , HEL (erythroid) ( 22 ) , HeLa (cervical) ( 4 , 13 , 21 , 28 , 32 , 37 , 43 ) , HeLa S3 (cervical) ( 30 , 36 ) , HL60 (myeloid) ( 2 ) , HOP62 (pulmonary) ( 24 ) , HUES-9 ('stem, embryonic') ( 31 ) , JEKO-1 (B lymphocyte) ( 15 ) , JHOC-5 ( 2 ) , JHOC8 ( 2 ) , Jurkat (T lymphocyte) ( 19 , 35 , 39 , 40 , 41 , 42 ) , K562 (erythroid) ( 21 , 37 , 44 ) , Kasumi-1 (myeloid) ( 22 ) , KG-1 (myeloid) ( 22 , 27 ) , liver ( 17 ) , LNCaP (prostate cell) ( 2 ) , lung ( 18 ) , MCAS (ovarian) ( 2 , 12 ) , MCF-7 (breast cell) ( 7 , 8 ) , MV4-11 (macrophage) ( 22 ) , NCEB-1 (B lymphocyte) ( 15 ) , NCI-H1395 (pulmonary) ( 24 ) , NCI-H157 (pulmonary) ( 24 ) , NCI-H1648 (pulmonary) ( 24 ) , NCI-H1666 (pulmonary) ( 24 ) , NCI-H2030 (pulmonary) ( 24 ) , NCI-H322 (pulmonary) ( 24 ) , NCI-H520 (squamous) ( 24 ) , OCI-ly1 (B lymphocyte) ( 15 ) , ovary ( 14 ) , OVCAR3 (ovarian) ( 2 , 12 ) , OVISE (ovarian) ( 12 ) , OVKATE (ovarian) ( 2 , 12 ) , OVMANA (ovarian) ( 2 , 12 ) , OVSAHO (ovarian) ( 2 , 12 ) , OVTOKO (ovarian) ( 2 , 12 ) , P31/FUJ (erythroid) ( 22 ) , PC3 (prostate cell) ( 2 ) , PC9 (pulmonary) ( 11 , 24 ) , Raji (B lymphocyte) ( 15 ) , RAMOS (B lymphocyte) ( 15 ) , REC-1 (B lymphocyte) ( 15 ) , RMG1 (ovarian) ( 2 , 12 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 16 ) , SH-SY5Y (neural crest) ( 2 , 16 ) , SKBr3 (breast cell) ( 23 ) , SU-DHL-4 (B lymphocyte) ( 15 ) , TCC-SUP (bladder cell) ( 2 ) , U-937 (myeloid) ( 2 ) , UPN-1 (B lymphocyte) ( 15 ) , Vero E6-S ('epithelial, kidney') ( 3 ) , WM239A (melanocyte) ( 10 )

Upstream Regulation
Treatments:	dasatinib ( 37 ) , LRRK2-IN-1 ( 16 )

Downstream Regulation
Effects of modification on SMARCA4:	ubiquitination ( 2 )
Effects of modification on biological processes:	carcinogenesis, induced ( 2 ) , cell growth, induced ( 2 ) , cell motility, induced ( 2 ) , chromatin organization, altered ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:	CCA ( 2 , 12 )

References
1	Borenäs M, et al. (2024) ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. Proc Natl Acad Sci U S A 121, e2315242121 38154064 Curated Info
2	Kimura A, et al. (2021) Phosphorylation of Ser1452 on BRG1 inhibits the function of the SWI/SNF complex in chromatin activation. J Proteomics 247, 104319 34237461 Curated Info
3	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
4	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
5	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
6	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
7	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
8	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
9	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
10	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
11	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
12	Kimura A, Arakawa N, Hirano H (2014) Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. J Proteome Res 13, 4959-69 25083560 Curated Info
13	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
14	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
15	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
16	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
17	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
18	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
19	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
20	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
21	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
22	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
23	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
24	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
25	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
26	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
27	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
28	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
29	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
30	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
31	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
32	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
33	Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72 20562096 Curated Info
34	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
35	Possemato A (2010) CST Curation Set: 9793; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
36	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
37	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
38	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
39	Possemato A (2009) CST Curation Set: 6371; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
40	Possemato A (2009) CST Curation Set: 6370; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
41	Possemato A (2009) CST Curation Set: 6368; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
42	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
43	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
44	Stokes M (2008) CST Curation Set: 4390; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info